Neurocrine's valbenazine misses in Phase IIb for Tourette syndrome

Neurocrine Biosciences Inc. (NASDAQ:NBIX) said valbenazine missed the primary endpoint in the Phase IIb

Read the full 148 word article

How to gain access

Continue reading with a
two-week free trial.